Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics Inc. (LUCD)
:LUCD
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.99Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 24, 2025
|% Change Since: 4.61%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant advancements in test volume, insurance coverage, and clinical validation. The company's financial position is strong, bolstered by recent financing. However, challenges remain in revenue recognition and the reimbursement environment, which are expected to improve with strategic efforts underway.Company Guidance
During the Lucid Diagnostics Fourth Quarter 2024 Business Update Conference Call, several key metrics and strategic developments were highlighted. The company reported $1.2 million in revenue for the fourth quarter, with a record quarterly test volume of over 4,000 EsoGuard tests, surpassing their target of 2,500 to 3,000 tests per quarter. Lucid Diagnostics achieved a significant milestone by securing positive commercial insurance coverage from Highmark Blue Cross Blue Shield of New York for EsoGuard, marking their first such coverage policy. They also noted that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines now include non-endoscopic biomarker testing as an acceptable alternative to endoscopy for esophageal precancer screening. Additionally, Lucid's recent strategic accomplishments included expanding their clinical evidence base with the publication of several clinical utility studies and securing an $8 million NIH grant to study an expanded indication for EsoGuard. Financially, the company ended the year with $22.4 million in cash, bolstered by a recent $15 million registered direct offering, providing a pro forma cash position of approximately $37 million as they enter the new year. Lucid is focused on ramping up revenue through expanded sales channels, including direct contracting with employers and a concierge medicine cash-pay program, with expectations for these initiatives to impact revenue in the second half of 2025.Record Quarterly Test Volume
Lucid Diagnostics achieved a record quarterly test volume with over 4,000 tests, surpassing their target of 2,500 to 3,000 tests per quarter.
First Commercial Insurance Coverage for EsoGuard
Highmark Blue Cross Blue Shield of New York established a positive commercial insurance coverage policy for EsoGuard, setting an important precedent for future engagements with commercial payers.
Expansion of Clinical Evidence Base
Lucid Diagnostics had two clinical utility studies accepted for peer-reviewed publication, bringing the total to five, establishing a strong chain of evidence for the clinical utility of EsoGuard.
Strong Financial Position
Lucid Diagnostics ended the year with $22.4 million in cash, and after a $15 million RDO financing, entered the new year with a pro forma cash of about $37 million.
NIH Grant Awarded for Expanded Indication
Lucid Diagnostics received an $8 million NIH grant to study EsoGuard for an expanded indication to include patients without heartburn, potentially increasing the total addressable market.
Positive NCCN Guidelines Update
The NCCN Clinical Practice Guidelines now include a section on screening for esophageal precancer, aligning with existing guidelines from the Gastroenterology Association, which supports EsoGuard.
---
LUCD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LUCD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 24, 2025 | $1.52 | $1.50 | -1.32% |
| Nov 13, 2024 | $1.00 | $1.05 | +5.00% |
| Aug 12, 2024 | $0.79 | $0.84 | +6.33% |
| May 13, 2024 | $0.94 | $0.95 | +1.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lucid Diagnostics Inc. (LUCD) report earnings?
Lucid Diagnostics Inc. (LUCD) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Lucid Diagnostics Inc. (LUCD) earnings time?
Lucid Diagnostics Inc. (LUCD) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LUCD EPS forecast?
LUCD EPS forecast for the fiscal quarter 2025 (Q1) is -0.16.
---